| Gene name: | TNF |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | EPC |
| Experiment: | SA-β-gal activity assay |
| Description: | Continuous treatment with TNF-α for 1 wk resulted in a dose-dependent increase in EPC senescence. There was a dose-dependent drop in the EPC population doubling rate with TNF-α treatment that mirrored the observed increase in cell senescence measured by SA-β-Gal staining. |
| Target gene: | P16 |
| Official symbol(s): | P16 |
| R-AG-Target gene: | Upregulation |
| Subcategory: | Unclear |
| Target gene experiment: | Flow cytometry |
| Target gene description: | We observed a marked up-regulation of p16INK4a expression after the continuous TNF-α treatment, as is shown in a representative flow cytometry histogram. |
| Regulatory pathway: | P38 MAPK |
| R-AG-Pathway: | Activation |
| Official symbol(s): | MAKP14 |
| Pathway experiment: | Western blot |
| Pathway description: | We first demonstrated that the p38 MAPK pathway was activated by TNF-α stimulation, as evidenced by phosphorylation of p38, and that the p38 MAPK inhibitor SB203580 is able to block this activation at a concentration of 10uM. |
Annotation:
Loading,please wait...